GeoVax Labs, Inc. has entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin® in combination with immune checkpoint inhibitors. The licensed technology, developed in collaboration with investigators at Emory University and Children's Healthcare of Atlanta, supports the use of gene-directed enzyme prodrug therapy to enhance the anti-tumor activity of checkpoint blockade.
David A. Dodd, Chairman and Chief Executive Officer of GeoVax, stated that this license strengthens the company's intellectual property position around Gedeptin-based combination therapies. "As checkpoint inhibitors continue to move earlier in treatment paradigms, including first-line and neoadjuvant settings, we believe Gedeptin's localized tumor-debulking and immune-sensitizing mechanism may provide an important opportunity to enhance and extend immune checkpoint inhibitor efficacy," Dodd explained.
The exclusive license provides GeoVax with global rights to patent applications and associated know-how covering the combination of Gedeptin with immune checkpoint inhibitors within a defined field of use. This intellectual property estate is intended to support GeoVax's current and planned clinical programs evaluating Gedeptin in combination with ICIs, including its recently announced neoadjuvant strategy in head and neck cancer and ongoing evaluation of additional solid tumor indications.
GeoVax has previously reported encouraging clinical and translational data demonstrating that Gedeptin's intratumoral delivery approach can induce localized tumor cell death while promoting immune activation within the tumor microenvironment. Dodd noted that while checkpoint inhibitors have transformed cancer care, many patients still fail to achieve durable responses. "The licensed Emory technology reinforces the scientific rationale for combining Gedeptin with ICIs to potentially convert immunologically 'cold' tumors into more responsive targets," he added.
The company has previously announced plans to evaluate Gedeptin in combination with immune checkpoint inhibitors in a Phase 2 neoadjuvant clinical trial in head and neck squamous cell carcinoma, as well as preclinical assessments in additional solid tumor settings. The Emory license provides a strengthened IP foundation to support these efforts and potential future partnerships. GeoVax continues to evaluate strategic collaboration opportunities related to both the clinical development and potential commercialization of Gedeptin-based combination therapies.
Gedeptin is a gene-directed enzyme prodrug therapy delivered intratumorally using a non-replicating viral vector encoding purine nucleoside phosphorylase. Following administration of a systemically delivered prodrug, the encoded enzyme converts the prodrug into a cytotoxic agent directly within the tumor microenvironment. This localized approach is designed to selectively destroy tumor cells while promoting immune recognition and minimizing systemic toxicity. Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers.
For business and technology leaders in the healthcare sector, this development represents a strategic move by GeoVax to strengthen its position in the competitive immuno-oncology landscape. The combination approach addresses a significant limitation of current checkpoint inhibitor therapies, potentially expanding treatment options for patients with solid tumors. The licensing agreement with Emory University, a leading research institution, provides scientific validation for the combination strategy while creating barriers to entry for competitors. As cancer treatment increasingly moves toward combination therapies and personalized approaches, this technology could position GeoVax as a significant player in next-generation oncology treatments. More information about the company's broader portfolio can be found at https://www.geovax.com.
